PH12013500545A1 - Oxadiazole inhibitors of leukotriene production - Google Patents

Oxadiazole inhibitors of leukotriene production

Info

Publication number
PH12013500545A1
PH12013500545A1 PH1/2013/500545A PH12013500545A PH12013500545A1 PH 12013500545 A1 PH12013500545 A1 PH 12013500545A1 PH 12013500545 A PH12013500545 A PH 12013500545A PH 12013500545 A1 PH12013500545 A1 PH 12013500545A1
Authority
PH
Philippines
Prior art keywords
compounds
leukotriene production
oxadiazole
inhibitors
oxadiazole inhibitors
Prior art date
Application number
PH1/2013/500545A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Todd Bosanac
Zhidong Chen
Lombaert Stã©Phane De
Jonathon Alan Dines
John D Huber
Weimin Liu
Pui Leng Loke
Tina Marie Morwick
Alan Olague
Doris Riether
Heather Tye
Lifen Wu
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12013500545A1 publication Critical patent/PH12013500545A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH1/2013/500545A 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production PH12013500545A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US201161533349P 2011-09-12 2011-09-12
PCT/US2011/052254 WO2012040139A1 (en) 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production

Publications (1)

Publication Number Publication Date
PH12013500545A1 true PH12013500545A1 (en) 2013-05-06

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500545A PH12013500545A1 (en) 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production

Country Status (19)

Country Link
US (1) US8575201B2 (en:Method)
EP (1) EP2619197B1 (en:Method)
JP (1) JP5713511B2 (en:Method)
KR (1) KR20130109122A (en:Method)
CN (1) CN103261193A (en:Method)
AU (1) AU2011305667A1 (en:Method)
BR (1) BR112013008638A2 (en:Method)
CA (1) CA2812449A1 (en:Method)
CL (1) CL2013000788A1 (en:Method)
CO (1) CO6710902A2 (en:Method)
EA (1) EA201300389A1 (en:Method)
EC (1) ECSP13012548A (en:Method)
IN (1) IN2013DN02555A (en:Method)
MX (1) MX2013003202A (en:Method)
PE (1) PE20131398A1 (en:Method)
PH (1) PH12013500545A1 (en:Method)
SG (1) SG188604A1 (en:Method)
WO (1) WO2012040139A1 (en:Method)
ZA (1) ZA201301747B (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物
EP2609092B1 (en) * 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
WO2012040137A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
BR112013008638A2 (pt) 2010-09-23 2016-06-21 Boehringer Ingelheim Int inibidores de oxadiazol de produção de leucotrieno
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
WO2014121055A2 (en) * 2013-02-04 2014-08-07 Janssen Pharmaceutica Nv Flap modulators
PL2875736T3 (pl) 2013-11-26 2017-02-28 Citrage N-karbamoiloputrescyna do zwiększenia syntezy białka mięśni

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206471B1 (en) 1999-08-06 2006-03-01 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
AU2004283080A1 (en) * 2003-08-13 2005-05-06 Novartis Vaccines And Diagnostics, Inc. GSK-3 inhibitors and uses thereof
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
ATE425158T1 (de) 2004-10-18 2009-03-15 Merck & Co Inc Diphenyl-substituierte alkane als flap- inhibitoren
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
CA2666686A1 (en) * 2006-09-01 2008-03-13 Merck & Co., Inc. Inhibitors of 5-lipoxygenase activating protein (flap)
US20100120784A1 (en) 2007-04-20 2010-05-13 Lachance Nicolas Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2010530419A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ジフェニル置換アルカン
JP2011500563A (ja) 2007-10-10 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ジフェニル置換されたシクロアルカン
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP5592388B2 (ja) * 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
TW201040175A (en) 2009-02-04 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
BR112013003439A2 (pt) * 2010-08-16 2019-09-24 Boehringer Ingelheim Int "inibidores de oxadiazol de produção de leucotrieno"
EP2609092B1 (en) * 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
WO2012040137A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
BR112013008638A2 (pt) 2010-09-23 2016-06-21 Boehringer Ingelheim Int inibidores de oxadiazol de produção de leucotrieno

Also Published As

Publication number Publication date
IN2013DN02555A (en:Method) 2015-08-07
CA2812449A1 (en) 2012-03-29
SG188604A1 (en) 2013-04-30
MX2013003202A (es) 2013-04-24
PE20131398A1 (es) 2013-12-19
AU2011305667A1 (en) 2013-03-21
CO6710902A2 (es) 2013-07-15
BR112013008638A2 (pt) 2016-06-21
EP2619197A1 (en) 2013-07-31
JP2013537909A (ja) 2013-10-07
ECSP13012548A (es) 2013-06-28
JP5713511B2 (ja) 2015-05-07
CL2013000788A1 (es) 2013-06-28
CN103261193A (zh) 2013-08-21
ZA201301747B (en) 2014-08-27
EP2619197B1 (en) 2015-08-05
WO2012040139A1 (en) 2012-03-29
US8575201B2 (en) 2013-11-05
US20120295896A1 (en) 2012-11-22
EA201300389A1 (ru) 2013-09-30
KR20130109122A (ko) 2013-10-07

Similar Documents

Publication Publication Date Title
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
HK1215256A1 (zh) 用作吲哚胺2，3-二氧化酶的抑制劑的化合物
PH12014500987A1 (en) Neprilysin inhibitors
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
WO2012122340A8 (en) Soluble guanylate cyclase activators
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
IN2012DN02139A (en:Method)
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
PH12017500595B1 (en) Aldosterone synthase inhibitors
IN2014DN09347A (en:Method)
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production